Cannabis and cannabinoids: MS Clinical Trials
3 active trials · 2 recruiting
3 active multiple sclerosis clinical trials involve Cannabis and cannabinoids, 2 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.
Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.
Active Cannabis and cannabinoids MS trials
RecruitingPhase 2
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Sponsor: Tiffany J. Braley, MD, MS
Cannabidiol (CBD) · Tetrahydrocannabinol (THC)
1 state166 participantsDetails ›
RecruitingPhase 2
Cannabis as a Complementary Treatment in Multiple Sclerosis
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Cannabis oil vs placebo
250 participantsDetails ›
Closed to new patientsPhase 2
Cannabis (THC vs. CBD) in Multiple Sclerosis
Sponsor: University of Calgary
THC · CBD
30 participantsDetails ›
MS trials by therapy
Exercise and rehabilitation (81)Ocrelizumab (Ocrevus) (34)Ofatumumab (Kesimpta) (18)Diet and nutrition (12)Teriflunomide (Aubagio) (9)Fingolimod (Gilenya) (8)Ublituximab (Briumvi) (7)Cladribine (Mavenclad) (7)Rituximab (6)Ozanimod (Zeposia) (6)Dimethyl fumarate (Tecfidera) (6)Interferon beta (5)Fenebrutinib (5)Stem cell therapy (aHSCT and MSC) (5)Natalizumab (Tysabri) (4)Siponimod (Mayzent) (4)Remibrutinib (4)CAR-T cell therapy (4)Alemtuzumab (Lemtrada) (3)Glatiramer acetate (Copaxone) (3)Frexalimab (3)Metformin (3)
